Redeye initiates coverage of BONESUPPORT

Redeye initiates coverage of BONESUPPORT, a long-term growth story in bone graft substitutes that we expect to resume its accelerating trajectory next year, particularly in the key US market, as impacts of the corona crisis fades. Nearer-term declines in the share over negative quarterly results would provide attractive entry points for investors.


Read more and download the research update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.